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Abstract: This mini-review summarizes the process of reverse-transcription, an obligatory 
step in retrovirus replication during which the retroviral RNA/DNA-dependent DNA 
polymerase (RT) copies the single-stranded genomic RNA to generate the double-stranded 
viral DNA while degrading the genomic RNA via its associated RNase H activity. The 
hybridization of complementary viral sequences by the nucleocapsid protein (NC) receives a 
special focus, since it acts to chaperone the strand transfers obligatory for synthesis of the 
complete viral DNA and flanking long terminal repeats (LTR). Since the physiological 
microenvironment can impact on reverse-transcription, this mini-review also focuses on 
factors present in the intra-cellular or extra-cellular milieu that can drastically influence 
both the timing and the activity of reverse-transcription and hence virus infectivity. 
Keywords: reverse transcriptase; nucleocapsid protein; genomic RNA; viral DNA; strand 
transfers; SEVI 
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1. Retroviruses as mobile elements in nature 
A unique feature of Retroviruses concerns their replication mechanism in host cells and organisms, 
a reverse transcription-integration process whereby the single-stranded viral RNA is copied by the 
viral DNA polymerase to generate the proviral DNA, which is integrated into the host cell DNA [1-9]. 
A genetic insertion such as this can impact on the life of the host and in some instances that of its 
descendants. In that respect, Retroviruses appear to be unique since no other infectious agent of higher 
eukaryotes is capable of integrating its genes into the host genome, of acquiring cellular genes into its 
own genome or has played such seminal roles in modern biology, biotechnology and in gene therapy 
[10-13]. 
Among Retroelements, the LTR-containing retrotransposons such as yeast retrotransposons (Ty) 
and human endogenous retroviruses (HERV) resemble simple retroviruses such as the 
gammaretrovirus murine leukemia virus (MuLV). In fact, these mobile elements encode the virion 
structural Gag proteins and Pol enzymes and contain non-coding regulatory sequences essential for 
genome replication, integration and expression such as the LTR (long terminal repeats). The 
endogenous retrotransposons that are abundant genetic elements in the host genetic make-up are 
probably playing key roles in genome reshuffling and variability. Thus, the replication of mobile 
retrotransposons by a transcription/reverse-transcription/integration process, also called ‘copy-and-
paste’, is thought to have fueled the evolution of eukaryotic genomes from yeast to human (Figure 1 
and legend) (reviewed in [14-17]). 
Retroviral particles or virions have a globular structure with a mean diameter of 100 nanometers. 
The virion outer envelope is of cellular origin and contains the viral glycoproteins called surface (SU) 
and transmembrane (TM), in the form of trimeric ensembles for HIV-1. The shape and oligomeric 
organization of the structural proteins of the inner core seem to be characteristics for each genera of 
the Retroviridae family. The virion genomic RNA is 6,000 to 12,000 nucleotides in length with a 
positive polarity, and resides within the core as a 60S RNA complex, where two full length viral RNA 
molecules interact with each other and are coated by several hundred nucleocapsid protein molecules 
(about 1500 molecules in the case of HIV-1 and MuLV [18-21]). 
Furthermore, it is important to briefly point out that actively replicating retroviral populations can 
have a complex composition, containing notably defective retroviruses which replicate only with the 
help of a replication competent retrovirus, called helper [4]. In fact, defective retroviruses commonly 
found in retroviral populations, need part or all of the functions of a fully competent retrovirus to 
replicate and disseminate in cells and organisms. Canonical defective retroviruses include highly 
oncogenic DLV’s (defective leukemia viruses) such as the Harvey and Kirsten MSV, which carries the 
v.ras oncogene flanked by retrotransposon VL30 sequences. The Moloney murine leukemia virus 
(MoMuLV) provides the viral helper functions in trans within the same cell to ensure co-replication of 
these DLV’s (see [22] for review). Viruses 2010, 2                                       
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2. Reverse transcription of the genomic RNA 
Forewords 
The reverse transcription reaction, whereby the positive strand genomic RNA serves as the 
template for the synthesis of a double-stranded DNA flanked by long terminal repeats (LTR), 
occurs during the early phase of virus replication, soon after virus infection of a target cell. The 
process of viral DNA synthesis by RT initially takes place in the virion core after its entry into the 
cytoplasm. The virion core is thought to undergo structural changes to become the reverse 
transcription complex (RTC; review of [20,21,23-25]). 
We will begin by providing a brief overview of viral DNA synthesis, from initiation to completion, 
with an emphasis on the interplay between RT, the viral nucleic acids and the nucleocapsid protein, the 
latter of which is an essential viral cofactor for viral nucleic acids and the RT enzyme. We will 
continue by reviewing factors that are believed to have an impact on reverse transcription, its fidelity 
as well as the potential variability of virus progeny. Finally, we will discuss recent findings on when, 
where and how reverse transcription takes place.  
a- Simplified scheme of the viral RNA template 
The 5’ and 3’ untranslated regions (UTR) of the full-length viral RNA are highlighted in Figure 3 
since they contain signals essential for reverse transcription from initiation to completion. The UTRs 
are made up of functional units referred to as R, U5 and PBS (5’ UTR), and PPT, U3, R and An (3’ 
UTR). Abbreviations stand for the Repeats (R), the untranslated 5’ and 3’ sequences (U5 and U3), the 
tRNA primer binding site (PBS), the polypurine tract (PPT) and the 3’ polyA tail (wavy line 
illustrating the 3' polyA tail) [26]. The cellular primer tRNALys,3 is represented by a cloverleaf-like 
molecule where modified bases (such as m6A at position 58 (see below)) are highlighted by black 
stars.. Although the genomic RNA is dimeric in a condensed 60S form within virions, only a single 
retroviral RNA molecule (gRNA) is shown here as a pseudo-circle, where the 5’ and 3’ ends are in 
close proximity. Note that the viral DNA polymerase (RT) and the NC protein molecules, which coat 
the genomic RNA, cannot be represented in this highly schematic flow diagram. Our understanding of 
reverse transcription has largely benefited from in vitro model systems to study the major steps of viral 
DNA synthesis (Figure 2). 
b- Primer tRNA annealing 
In most retroviruses the PBS is 18 nt in length and annealing of replication primer tRNA, - 
tRNALys,3 for Lentiviruses - via its complementary 3’ 18 nt is promoted by means of the RNA 
annealing activity of NC proteins. This RNA annealing activity is exhibited by both the polyprotein 
Gag precursor and the mature NC protein (reviewed in ([27]) and results in the formation of a perfect 
18 nt long double-stranded RNA between the viral PBS and primer tRNA (Figure 3a, b). Further 
nucleotide interactions have been reported to take place between tRNALys,3 and motifs flanking the 
PBS in HIV-1, notably the A rich polyA stem-loop [25-27]. 
 Viruses 2010, 2                                       
 
 
942
Figure 1. Schematic representation of the replication of a simple retrotransposon.  
a. The genomic RNA is a unique RNA synthesized by transcription of the integrated 
retrotransposon DNA. b.-c. The RNA copy is exported from the nucleus and translated by 
the cellular translation machinery – ribosomes are illustrated here - to produce the Gag and 
GagPol like polyprotein precursors. d.-e. During formation of a ribonucleoparticle (RNP) 
called VLP (virus-like particle or VLP) the Gag and GagPol precursors undergo maturation 
by a Pol-encoded protease. At the same time the RNA copy of the retrotransposon, together 
with the replication primer tRNA are incorporated into the VLP. Note that the VLP’s 
remain in the cytoplasm and are not exported (cross) contrary to replication-competent 
retroviruses. f. Reverse transcription of the RNA copy is carried out by the RT and is 
chaperoned by NC-like proteins in the VLP nucleoprotein structure to generate a new copy 
of retrotransposon DNA. g.-h. The new DNA copy is imported into the nucleus and 
integrated into the host cell genome by the Pol-encoded integrase to complete the copy-
and-paste process. 
h-DNA Integration (IN)
a-DNA Transcription
c-RNA translation
e-VLP assembly
and formation (NC)
g-Nuclear import of DNA
b-RNA nuclear export
d-RNA packaging (NC)
f-RTion: RNA+RT+NC
 
 
c- Initiation of viral DNA synthesis 
RT recognizes the terminal 3’ OH of the annealed tRNA to initiate reverse transcription and 
synthesis of the minus-strand strong-stop cDNA (sscDNA) by copying the genomic RNA (thick black 
line) (Figure 3c). Other factors have been found to contribute to RT recruitment onto the viral initiation Viruses 2010, 2                                       
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site such as tRNA nucleotide modifications at the level of the anti-codon loop and NC protein 
(reviewed in 21). At the end of sscDNA synthesis, the 5’ gRNA sequences exist in a DNA:RNA hybrid 
and undergo degradation by the RT-associated RNaseH activity [28] (reviewed in [29]) resulting in the 
formation of a single-stranded DNA covalently linked to the primer tRNA. The RNase H activity 
appears to be enhanced by NC protein in the course of and following vDNA synthesis, probably by 
promotion of the release of small RNA degradation fragments generated by RNase H [29-30]. 
d- Transfer of sscDNA 
The first DNA strand transfer corresponds to a hybridization reaction between the ss-cDNA 3’ R(-) 
and gRNA 3’ R(+) sequences, which is required to resume reverse transcription of the gRNA and to 
synthesize the 3’ LTR. This hybridization reaction between the R(-) and R(+) sequences is directed by 
NC protein [30,32] (reviewed in [20-21]) According to in vitro analysis on HIV-1, it appears that both 
the TAR upper loop and the R ends are important for this annealing reaction [33] (Figure 3d). 
e-f- Minus strand cDNA synthesis 
The minus-strand sscDNA is extended by RT by copying the gRNA up to the 3’ end of the PBS 
while at the same time the genomic RNA template is being degraded by the RT-RNase H activity 
(Figure 3e). Interactions between the RT enzyme and NC protein molecules augment the processivity 
of the reaction in vitro as well as its fidelity by providing a degree of excision-repair activity to RT in 
HIV-1 [20,34] and MuLV (Darlix et al., unpublished data). 
g- Initiation of plus-strand DNA synthesis 
The plus-strand primer or polypurine tract (PPT) directs initiation of plus-strand DNA synthesis as 
a result of a sequential process: (i) minus-strand DNA synthesis over the PPT, (ii) RT-RNase H 
cleavage at the PPT 3' end, which allows initiation (iii) of plus-strand DNA synthesis from the nascent 
RNA primer (Figure 3f) with the help of NC protein [35,36]. 
Later in the course of reverse transcription the PPT RNA is removed by the RT-RNase H activity. 
RT synthesizes plus-strand DNA (gray line) [37-38] by extension of the genomic PPT RNA and 
continues up to the methylated A residue at position 58 of primer tRNALys,3 [38]. This results in the 
formation of a double-stranded DNA encompassing the U3, R and U5 sequences, corresponding to the 
full-length 3’ LTR and in the release of the remaining tRNALys,3 sequences by the RT RNaseH 
activity, freeing the 3’ end of the newly made plus- and minus-strand DNA. 
h- Plus-strand DNA transfer 
This step corresponds to a hybridization reaction between the minus- and plus-strand viral DNA at 
the level of the PBS sequences (see ref. [39] for detail), in a reaction directed by NC protein in vitro 
(Figure 3g, h)(reviewed in [20-21]). Subsequently the two viral DNA strands are extended by RT, the 
plus-strand by copying the newly made minus-strand viral DNA, on the one hand, and the final 
extension of the minus-strand viral DNA by copying the plus-strand DNA, which requires DNA strand 
displacement, ultimately leading to 5’ LTR formation, on the other hand. Viruses 2010, 2                                       
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Figure 2. In vitro model systems to study retroviral reverse transcription. Flexible in 
vitro model systems have been set up to study in detail the process of retrovirus reverse 
transcription [21,23-25,30]. Such models include (i) in vitro generated RNA (vRNA) 
representing the 5’ and 3’ UTR domains containing the cis-acting elements essential for 
cDNA synthesis, namely the PBS, the binding site for the replication primer tRNA, the 
untranslated 5’ and 3’ regions (U5 and U3), the repeats (R in blue) and the polypurine tract 
(PPT); (ii) Replication primer tRNA of natural origin (P-tRNA) or generated by in vitro 
transcription, or a synthetic oligonucleotide complementary to the PBS; (iii) the RT 
enzyme (not shown); (iv) NC protein (not shown); (v) if required, the IN enzyme, VIF, 
VPR and cellular factors such as SEVI [31]. 
In vitro models such as this have rendered possible a detailed investigation of the essential 
steps of reverse transcription, following tRNA annealing to the PBS by NC:  
a-  initiation of ss-cDNA synthesis (see large orange arrow); 
b-  the first strand transfer which corresponds to an annealing reaction chaperoned  
    by NC and requiring the R sequences (white arrow) [31-32]; 
c-  minus-strand cDNA elongation (double orange arrow); 
d-  initiation of plus-strand DNA synthesis and transfer (not shown here for the  
    sake of clarity; see also Figure 3); 
e-  the fidelity of the strand transfer and of cDNA synthesis by RT and the    
    influence of RT mutations; 
f-  the role of the RT-associated RNase H activity on the strand transfer; 
g-  the role of NC on DNA strand transfer and the fidelity of reverse transcription  
    via its interaction with RT and the vRNA; 
h-  the influence of vRNA mutations, incubation conditions (ions, temperature,  
   nucleotides  etc.) and viral and cellular factors such as VIF, SEVI.  
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i-j- The proviral DNA 
A double-stranded linear DNA with the two flanking LTR’s is the final product of the reverse 
transcription process and its maintenance, notably of the inverted repeats (ir) that are required for 
integration by the viral integrase enzyme (IN), is ensured by NC protein and IN molecules (Figure 3i) 
[40-41] (reviewed in [20]). This viral DNA, also called proviral DNA, is actively imported into the 
nucleus within a preintegration complex (PIC) and is subsequently integrated into the host cell genome 
by IN in the form of a tetramer with the help of the cellular cofactor LEDGF [8,42-43]. Recently 
developed anti-HIV-1 drugs were found to efficiently inhibit the integration reaction in vitro and in 
vivo [44]. 
3. Reverse transcription of subgenomic and cellular RNAs 
The full length viral RNA, in addition to being the retroviral genome, plays a key role early in 
retrovirus assembly since it represents a scaffolding platform onto which Gag polyprotein molecules 
readily assemble to ultimately form the inner core structure [45-47]. In addition to the dimeric RNA 
genome, which is the reverse transcription template, the mature virion core structure contains 
subgenomic and a subset of cellular RNAs that can be reverse transcribed. 
a. Virion incorporation of subgenomic viral RNAs 
Significant amounts of subgenomic viral RNAs are packaged into virions alongside the full length 
viral RNA [49-51]. Under conditions where the full length viral RNA has had the Psi packaging signal 
removed, only minute amounts of genomic RNA are incorporated into virions, while the incorporation 
of subgenomic RNA is favored (for review : [52]) [49,53-55]. The spliced viral RNAs are believed to 
be dimeric within the virion core since they are able to undergo dimerization in vitro, a prerequisite for 
RNA packaging [51,56-57]. All spliced HIV-1 RNA species have been found equally packaged in 
virions, regardless of their nuclear export pathway [49]. While genomic RNA packaging is mediated 
through Gag or NC interaction, involving the characteristic zinc finger domains, the spliced HIV 
RNAs are dependent upon the SP1 region of Gag for their packaging [54]. However, all HIV-1 RNA 
species share common functional cis-acting packaging signals, notably those in the 5’ UTR, since both 
the genomic RNA and the spliced viral RNA species are packaged in a competitive manner [49]. The 
subgenomic RNAs contain all the cis-acting signals recognized by RT, and reverse transcription of 
notably the fully spliced viral RNAs takes place in virions and in newly infected cells as efficiently as 
that of the unspliced viral RNAs [50]. In the case of gammaretroviruses, MuLV provides the unique 
example of a natural heterodimer. Despite the presence of spliced and genomic RNA within virions, 
genomic dimers are the predominant form observed undergoing reverse transcription [51,58]. 
b. Incorporation of cellular RNAs into virions 
In the course of virion morphogenesis, abundant cellular RNAs are incorporated into viral particles, 
which, in the case of wild-type retroviral particles, reside in the core together with the genomic RNA. 
Interestingly, incorporation of cellular RNAs into viral particles is greatly enhanced when the genomic 
RNA lacks the Psi packaging signal. Under these conditions, cellular RNAs can constitute more than Viruses 2010, 2                                       
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50% of the total RNA mass per particle [46,49]. These cellular RNAs might participate in 
recombination-transduction reactions during reverse transcription, for example defective leukemia 
viruses have been generated through this process [59-64]. 
Figures vary for the extent of cellular RNA incorporation into virions since RNA can be selectively 
excluded or enriched for in retroviral particles. Among abundant species, there are many small Pol-III-
generated RNAs such as tRNA, 5S rRNA, U6 snRNA, mY RNAs, 7SL RNA and 7SL RNA-derived 
SINE RNAs (B1 RNA or Alu RNA) [49,64-68]. For unknown reasons, the U6 snRNA is enriched in 
RSV, MuLV or HIV-1 particles, while U1 and U2 snRNAs are found only in trace amounts. 
Figure 3. Illustration of the reverse transcription process. The individual steps are as 
follows.  a.-b. annealing of the replication primer tRNA by NC. Stars correspond to 
modified nucleotides in the primer tRNA, notably m6A at position 58 important for the 
fidelity of the plus-strand DNA transfer and in the anti-codon loop recognized by RT.  
c. Initiation of cDNA synthesis by RT by extension of the –CCA 3’ terminal nucleotides.  
d. SscDNA(-) transfer to the RNA 3’ R sequences by NC. e. minus -trand DNA transfer by 
RT. f. Initiation of plus-strand DNA by extension of the PPT RNA by RT. g.-h. Plus-strand 
DNA transfer at the level of the PBS sequences by NC and elongation of viral DNA 
strands by RT that includes ds DNA unwinding to complete LTR DNA synthesis. i. The 
linear ds DNA is shown here with the LTR’s and the terminal TG/CA nucleotides. 
 Viruses 2010, 2                                       
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The 7SL RNA exemplifies specific host RNA encapsidation since it is enriched at a level similar to 
that of the genomic RNA in MuLV and HIV-1 virions [65-66]. In addition, the 7SL RNA can be 
reverse transcribed in virions and in newly infected cells [67]. 
Similarly, mY RNAs are among the most highly represented non-coding RNAs specifically 
packaged in MuLV. Interestingly, mY RNAs are recruited even in Ro60 knockout cells, where mY 
RNA is degraded in the cytoplasm while there is a residual pool in the nucleus [68-69]. These 
observations favor the notion that mY RNAs are recruited in the nucleus of infected cells, at an early 
stage of MuLV morphogenesis. Except for the replication primer tRNAs that are packaged through 
interaction with viral RT and possibly NC [70-72], the packaging determinants of host cell RNAs are 
poorly defined. Recent studies have indicated that selective packaging of host RNAs such as U6 
snRNA or 7SL RNA, is controlled through independent mechanisms that differ from those of viral 
RNAs [49,64,66]. A possible mechanism through their heterodimerization with the viral genomic RNA 
is unlikely [51]. Packaging of 7SL RNA has been studied the widest, but its NC-dependence, and its 
possible influence on APOBEC3G packaging are questioned by others [73]. 
Taken together, the mechanism by which non-genomic, viral and cellular RNAs are packaged into 
virions is as yet poorly understood, or controversial, with the exception of the primer tRNA. The roles 
of subgenomic RNA and some cellular RNAs in reverse transcription and in the biology of the virus 
remain a matter of speculation, with the notable exception of the replication primer, and of 7SL RNA, 
thought to recruit the APOBEC 3G restriction factor [70,74]. 
4. Viral DNA Synthesis during retrovirus assembly 
The overall process of Retrovirus assembly is considered to take place at the plasma membrane of 
infected cells where Gag and Gag-Pol molecules assemble via major interactions between two 
platforms, the N-terminal myristate and basic residues of the Gag-Matrix with plasma membrane 
phospholipids, and the zinc finger and the flanking basic residues of the Gag-NC with the genomic 
RNA (reviewed in [75-79]). Once completed, immature retroviral particles bud from the plasma 
membrane. Next, virion Gag and Pol molecules are processed by the viral protease (PR) during which 
condensation of the inner core occurs and virions gain infectivity [80-81]. However, retroviral 
assembly can also take place within infected cells, notably at the level of intracellular membranes such 
as endosomes and multivesicular bodies [82-85]. Under these circumstances the viral protease can 
readily remain active during assembly, directing the processing of Gag and Gag-Pol polyprotein 
precursors. Indeed, a large body of evidence obtained by western immunobloting demonstrates the 
presence of mature matrix, capsid and nucleocapsid proteins in cytoplasmic extracts of infected cells. 
Furthermore, the newly made virions contain a single copy of the full length viral RNA in a dimeric 
form along with minor quantities of spliced RNAs (see above) [49]. 
However, it has long been shown that small amounts of minus-strand viral DNA are present in viral 
particles of Rous sarcoma virus (RSV), Moloney murine leukemia virus (MoMuLV), and HIV-1 
generated in cell cultures. This indicates that reverse transcription can already be ongoing during virus 
assembly or in the released particles, in a process which has been called natural endogenous reverse 
transcription (NERT) [86-89]. This early or premature reverse transcription has been extensively 
studied by the groups of Pomerantz and Mougel [50,90], revealing that AZT treatment of HIV-1 Viruses 2010, 2                                       
 
 
948
infected T cells causes a 10-100 fold reduction of intravirion viral DNA levels. This supports the 
notion that reverse transcription can take place, at least in part during the course of virus assembly as 
suggested some time ago in studies demonstrating that the synthesis of a complete infectious viral 
DNA can take place within virions of MoMuLV and equine infectious anemia virus (EIAV) under in 
vitro conditions using mild detergents that preserve the core integrity [92-93].More importantly, the 
physiological microenvironment, notably components of seminal fluid such as polyamines, dNTP’s 
and fragments of the abundant semen marker prostatic acidic phosphatase (PAP)s, can drastically 
enhance NERT and the accumulation of intravirion viral DNA [31-90]. HIV-1 virions containing high 
levels of viral DNA can readily infect non-dividing target cells. In addition, the PAP-derived peptide, 
termed Semen-derived Enhancer of Virus Infection (SEVI) that is also abundant in seminal fluid can 
efficiently promote attachment of HIV-1 particles to target cells. This in turn enhances viral infection 
and most probably facilitates the very early events of HIV-1 infection during sexual intercourse 
[31,90,91].  
Furthermore, SEVI seems to display a potent nucleic acid chaperoning activity and to greatly 
enhance the reverse transcription process in vitro as well as in HIV-1 virions (Darlix JL et al., 
unpublished data), which suggests that SEVI might act as a multifunctional cofactor enhancing HIV-1 
infection through numerous modes.  
Taken together these findings show that viral DNA synthesis can indeed start during virus formation 
and that the so-called NERT process is largely influenced by components of the physiological 
microenvironment such as polyamines, dNTP’s and SEVI. This in turn can have a significant impact 
on HIV-1 infectivity of primary target cells [89-91]. 
Arguably, Retroviruses such as HIV should be viewed as RNA/DNA viruses rather than being 
strictly categorized as RNA viruses. Furthermore, the evidence highlights the need to identify 
microbicide compounds aimed at inhibiting components of the seminal fluid which facilitate HIV-1 
infection [94]. 
5. Retrovirus assembly and the control of reverse transcription 
In the course of assembly, Gag structural precursor molecules are targeted to the plasma membrane 
by the N-myristate and basic residues of the Gag matrix (MA) on the one hand, and the genomic RNA, 
notably the Psi Packaging signal (its stem-loops specifically bound by the C-terminal Gag 
nucleocapsid (NC)), on the other. In fact, NC – consisting of either one or two highly conserved zinc 
fingers flanked by basic residues – directs the selection of the genomic RNA through multiple 
interactions between the RNA Psi sequences and both its zinc finger(s) and its basic residues 
[20,21,75,95]. 
In the case of HIV-1 NC, the central globular domain corresponding to the two zinc fingers and the 
basic linker forms a hydrophobic platform which specifically binds the Psi stem-loops of the genomic 
RNA (reviewed in [21,75]). Mutating the highly conserved CCHC residues of the zinc fingers causes 
an impairment of genomic RNA packaging in newly formed virions. Interestingly, these CCHC 
mutations result in profound modifications of Gag trafficking in cells and in the production of viral 
particles that are completely replication defective (reviewed in [20,95]). Viruses 2010, 2                                       
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However reverse transcription does take place in CCHC mutant virions as evidenced by the 
accumulation of newly made viral DNA ([96-97], and ref. herein), which does not, however undergo 
integration. The observed reverse transcription occurs during assembly and prior to virion budding 
because addition of the nucleoside RT inhibitor (NRTi) AZT to the producer cells blocks accumulation 
of the viral DNA. This newly synthesized viral DNA, or at least part of it, was found to be functional 
since it was capable of promoting synthesis of the viral Tat transactivator and of LTR activation ex vivo 
[96]. 
The above data highlight the fundamental role of NC in virus assembly and reverse transcription, 
and possibly in the maintenance of the newly made viral DNA [40] (reviewed in [20,95]). In addition, 
there seems to be a tight connection between virus assembly and the start of reverse transcription 
where slowing down or modifying the assembly process would be expected to modify the timing of 
viral DNA synthesis. The data also favor the notion that minor structural modifications of the inner 
virion core would result in the intracellular instability of newly made viral DNA, notably at the 5’ and 
3’ ends. Indeed, mutating the NC zinc fingers results in the formation of HIV-1 particles with a general 
globular structure and not a condensed cone-shaped structure as typified by the wild type virus [99], 
which result in degradation of the incoming virion core by cellular factors (see § on the synthesis of 
functional viral particles in primary cells, below). 
In support of such a dynamic connection between virus assembly and budding, and viral DNA 
synthesis, Thomas et al. [98] reported that mutating the p6 PTAP motif within the Gag C-terminal 
domain slowed virion budding, an effect probably due to weakening of the interaction between Gag 
and the cellular transporter protein TSG101. At the same time, this causes extensive premature reverse 
transcription and the accumulation of newly made viral DNA in p6 mutant virions. 
Thus, the general view that emerges suggests that the dynamics of the assembly-budding process 
exert tight control on the timing of viral DNA synthesis by RT, chaperoned by NC in the virion core. 
Furthermore, the global structure of the core, central to which the multiple interactions between NC 
molecules and the genomic RNA, would transiently function as a shield against cellular factors 
capable of degrading components of the viral core, which would otherwise prevent synthesis of a 
functional viral DNA. For highly replicating viruses such as HIV-1, the nature of the molecular 
interactions between the genomic RNA, tRNA, RT and NC, and between the viral DNA, NC and IN 
largely out competes the influence of host restriction factors such as APOBEC and TRIM proteins. In 
addition, these tight molecular interactions might well be indispensable for the synthesis of complete 
viral DNA containing mutations and reassortment of large regions by means of recombination 
reactions. This should confer, at least in part, resistance to immune  responses and  anti-retroviral 
therapies targeting the RT, PR and IN enzymes (HAART). 
6. Reverse transcription in primary cells 
In cells undergoing HIV-1 infection, the process of reverse transcription occurs in a densely 
populated environment, the cytoplasm. There, it is intimately linked to at least two other steps, namely 
uncoating, the process through which the viral core is reorganized, and trafficking towards the nucleus 
[100]. Given that reverse transcription occurs in this viral shell that serves several functions, it is not 
surprising that this process is intimately linked to the fate of viral cores. Indeed, mutations that affect Viruses 2010, 2                                       
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the core major structural component, (i.e. the Capsid protein (CA)), almost invariably display a defect 
in viral DNA accumulation [100-103]. 
However, the relationship between HIV-1 reverse transcription and viral core reorganization is 
poorly understood. Specifically, it is not known whether uncoating occurs subsequent to the 
completion of viral DNA or if a reciprocal co-stimulation is established between the two processes. 
The former hypothesis was raised following evidence indicating that viral cores gained stability in the 
absence of the central polypurine tract -central termination sequence (cPPT-CTS) cis-element [104]. In 
this debated model, the three-stranded DNA flap formed in the neo-synthesized viral DNA, conveys 
the signal of end of reverse transcription which starts viral core restructuration and prepares it for the 
next step of the viral life cycle, i.e. nuclear import. This model is seducing as it finds parallels in other 
viruses whose capsids undergo profound changes in the proximity of nuclear pores that are required 
for the nuclear import of their genome [104-106]. Whether this is true for HIV-1 remains a matter of 
debate as biochemical evidence suggests that extensive viral core reorganization occurs either prior to 
or during reverse transcription [107-110] and cPPT-CTS mutants display rather moderate infectivity 
defects [111-113]. 
Why is the relationship between reverse transcription and uncoating important? We propose it is so 
to counteract in a timely fashion possible antiviral defenses that target viral cores. Viral cores are 
characteristic molecular signatures of Retroviruses and they are known to be targeted shortly after cell 
entry by antiviral factors. For example, the Tripartite motif protein 5 alpha (TRIM 5α) recognizes viral 
cores and destructures them, impacting on reverse transcription (108). If uncoating does not occur until 
the completion of viral DNA synthesis, then a structure identical to the one entering the cell will be 
present throughout the journey of the viral core across cytoplasm. If, instead, uncoating occurs 
progressively together with reverse transcription this characteristic complex will undergo change, as a 
consequence of which the viral structures sensed by cellular antiviral defenses will be markedly 
distinct. 
It remains to be seen if TRIM5α or the Friend susceptibility virus gene 1 (Fv1) are unique factors or 
if other proteins exert similar functions, but it would not be surprising to find these characteristic 
retroviral structures to be the target of multiple factors. In this respect, by providing a signal for the 
ordered reorganization of viral cores, reverse transcription may protect the virus from attack within the 
cytoplasm environment simply by promoting shedding of the components through which viral cores 
are recognized.  
The major difference between the two models outlined above on the relationship between core 
reorganization and reverse transcription is the length of time during which the initial viral core 
structure persists as such in the cytoplasm of infected cells. It is well appreciated that viral DNA 
completion varies greatly among target cells. For example, while the reverse transcription process 
takes only 4 to 8 hours in transformed cell lines such as HeLa cells, widely used to study viral 
infection, it can take up to 20-30 hrs in primary lymphocytes and macrophages or days in non-
stimulated monocytes [114-116]. Thus, the extent of reverse transcription in different target cells is 
extremely variable and dependent on the activation status of target cells, the dNTP pool and on the 
plethora of cellular factors that are present in these cells at the moment of infection. In cells in which 
reverse transcription occurs slowly, antiviral defenses are more likely to recognize and counteract 
incoming virion cores.  Viruses 2010, 2                                       
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Indeed a correlation between the extent of reverse transcription and the permissivity of primary 
cells to infection is widely reported. In the past, this has been hypothesized to be a consequence of 
poor availability of dNTPs in cells resistant to infection. Yet, more recent data indicates that RT 
functions correctly even at low dNTP concentrations, such as those normally found in restrictive cells 
including macrophages or monocytes [116,117]. It is thus conceivable that the correlation between the 
rate of reverse transcription and a cell’s susceptibility to infection is due to a protective effect of the 
viral core permitting more efficient reverse transcription and thus infection. 
One of the major problems in studying the early phases of infection is the long appreciated 
observation that the vast majority of viral particles entering cells are non-infectious, as they do not 
result in the establishment of an integrated proviral DNA and are progressively lost over time. Only 1 
in 8 viruses is thought to be infectious in established cell lines where infection is efficient [118] but 
may well be at least 1 in 100 particles in primary cell types such as macrophages and dendritic cells. 
The reasons for this are unclear at present and defects at the level of viral assembly cannot be 
excluded. Yet, an interesting hypothesis is that intracellular defenses are largely responsible for the 
generation of non-infectious viruses, in which replication terminates at some point despite successful 
target cell entry and initiation of reverse transcription. This hypothesis remains unaddressed. 
7. Conclusion 
Studying reverse transcription in HIV-1 has shed some light on virus variability fueled by the error 
prone RT enzyme, which is, at least in part, counterbalanced by NC protein in order to control the 
process and to contribute to its completion and fidelity (Figure 4). At the same time, NC and NC-RNA 
interactions most probably drive the incorporation of cellular deaminase APOBEC 3G, which should in 
turn contribute to HIV-1 variability (Figure 4), though it in turn counterbalanced by the viral factor 
VIF. 
To understand how HIV-1 genetic variability allows the virus to resist innate defenses, specific 
immunological responses and highly active antiretroviral therapies targeting the viral enzymes RT, PR 
and IN (HAART) [119], the circulating virus populations should be viewed as quasi-species consisting 
of genetically distinct but closely related viruses. Analysis of HIV-1 proviral DNA in individual T-cells 
present in the lymph nodes of infected persons shows a substantial fraction harbor distinct proviruses 
[120]. It follows that infected T-cells possess the ability to produce both homozygous and 
heterozygous viruses by means of recombination during reverse transcription, further fueling HIV-1 
variability [18,21,121-122] and translates into the generation of a large number of virus quasi-species. 
Since the nucleocapsid protein of HIV-1 plays key roles in reverse transcription, mainly through its 
highly conserved zinc fingers, it represents a target of choice for compounds and approaches [123] that 
seek to complement HAART and impair the circulation of HIV-1 strains resistant to anti-RT, -PR and –
IN drugs [120].  Viruses 2010, 2                                       
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Figure 4. Molecular interactions in the course of reverse transcription. This scheme 
illustrates essential molecular interactions taking place prior to and during reverse 
transcription. (i) The genomic RNA is in a dimeric form where there are many RNA-RNA 
interactions, in addition to the Dimer Linkage Structure (DLS). (ii) Several hundred NC 
molecules, in a poorly characterized oligomeric form [72] (see top arrow pointing to NC-
NC interactions), coat the genomic RNA providing protection against cellular nucleases 
and UV irradiation; (iii) A number of small cellular RNAs are incorporated into virions via 
interactions with Gag-NC and Pol-RT and Pol-IN (not illustrated here); except for the 
primer tRNA the function, if any, of the other cellular RNAs is poorly understood. (iv) The 
RT and IN enzymes interact with the genomic RNA-NC complex ensuring reverse 
transcription and ultimately integration of the newly made viral DNA. (v) In the absence of 
the viral factor VIF, APOBEC restriction factors are incorporated into virions via 
interactions with the viral RNA and NC, which results in the production of highly mutated 
viral DNA molecules. (vi) The reverse transcription machinery is housed within the 
incoming virion core where capsid protein molecules provide protection against host 
restriction factors such as TRIM proteins (see also text). (vii) Small amounts of the viral 
transactivator TAT have been found in the virion core. Tat may counteract the negative 
impact of cellular miRNA on the stability of the viral RNA prior to virion formation [124]. 
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